- Home
- NBB vs ORGO Comparison
NBB vs ORGO Comparison
Compare NBB & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBB
- ORGO
- Stock Information
- Founded
- NBB 2009
- ORGO 1985
- Country
- NBB United States
- ORGO United States
- Employees
- NBB N/A
- ORGO N/A
- Industry
- NBB Finance Companies
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- NBB Finance
- ORGO Health Care
- Exchange
- NBB Nasdaq
- ORGO Nasdaq
- Market Cap
- NBB 462.1M
- ORGO 384.4M
- IPO Year
- NBB N/A
- ORGO N/A
- Fundamental
- Price
- NBB $15.49
- ORGO $3.46
- Analyst Decision
- NBB
- ORGO Buy
- Analyst Count
- NBB 0
- ORGO 2
- Target Price
- NBB N/A
- ORGO $5.50
- AVG Volume (30 Days)
- NBB 73.9K
- ORGO 911.8K
- Earning Date
- NBB 01-01-0001
- ORGO 08-07-2025
- Dividend Yield
- NBB 8.64%
- ORGO N/A
- EPS Growth
- NBB N/A
- ORGO N/A
- EPS
- NBB N/A
- ORGO N/A
- Revenue
- NBB N/A
- ORGO $458,760,000.00
- Revenue This Year
- NBB N/A
- ORGO $2.62
- Revenue Next Year
- NBB N/A
- ORGO $12.46
- P/E Ratio
- NBB N/A
- ORGO N/A
- Revenue Growth
- NBB N/A
- ORGO 5.35
- 52 Week Low
- NBB $13.67
- ORGO $2.28
- 52 Week High
- NBB $16.66
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- NBB 49.65
- ORGO 54.42
- Support Level
- NBB $15.29
- ORGO $3.13
- Resistance Level
- NBB $15.59
- ORGO $3.36
- Average True Range (ATR)
- NBB 0.16
- ORGO 0.21
- MACD
- NBB -0.01
- ORGO 0.08
- Stochastic Oscillator
- NBB 42.39
- ORGO 74.36
About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest
Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests primarily in a diversified portfolio of taxable municipal securities.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.